GKOS - Glaukos inks new licensing deal for Preserflo MicroShunt with Santen

Glaukos (GKOS) has entered into a new development and commercialization license agreement with Santen Pharmaceutical (SNPHF) for the Preserflo MicroShunt (DE-128), superseding the previous agreements between the two parties. Under the new agreement, Glaukos obtains exclusive commercialization rights for the MicroShunt in the U.S., Australia, New Zealand, Canada, Brazil, Mexico and the remainder of Latin America.Financial terms of the deal were not disclosed.The new agreement also provides Glaukos with full control over all development activities for the MicroShunt in these same territories.Santen will continue to manufacture and supply the MicroShunt for the Glaukos territories and lead development and commercialization activities elsewhere. The Preserflo MicroShunt is an ab-externo, drainage system that helps drain eye fluid and reduces intraocular pressure in patients with primary open-angle glaucoma. Made of a proprietary, biocompatible material called SIBS, the Preserflo MicroShunt is a flexible, 8.5-mm-long tube with planar fins to help fixate the device in the

For further details see:

Glaukos inks new licensing deal for Preserflo MicroShunt with Santen